Cost-effectiveness analysis of the Neuropad device as a screening tool for early diabetic peripheral neuropathy [0.03%]
用于筛查早期糖尿病外周神经病的Neuropad装置的成本效益分析
B Rodríguez-Sánchez,L M Peña-Longobardo,A J Sinclair
B Rodríguez-Sánchez
Objective: To carry out a cost-effectiveness analysis of the use of Neuropad as a screening test for diabetic neuropathy together with the standard care tool, the 10-g monofilament, in people with diabetes. ...
Trends in rates of orthopedic surgery in Germany: the good, the bad, and the ugly [0.03%]
德国骨科手术率的现状：有好有坏也有丑恶的一面
Afschin Gandjour
Afschin Gandjour
Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach [0.03%]
结直肠癌治疗的生存率及成本和改变治疗策略的影响：一种模型方法
Paal Joranger,Arild Nesbakken,Halfdan Sorbye et al.
Paal Joranger et al.
New and emerging advances in colorectal cancer (CRC) treatment combined with limited healthcare resources highlight the need for detailed decision-analytic models to evaluate costs, survival and quality-adjusted life years. The objectives o...
Gretta Mohan,Anne Nolan
Gretta Mohan
Co-payments for prescription drugs are a common feature of many healthcare systems, although often with exemptions for vulnerable population groups. International evidence demonstrates that cost-sharing for medicines may delay necessary car...
Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data [0.03%]
基于真实世界队列数据的复发性多发性骨髓瘤卡非佐米联合来那度胺和地塞米松治疗的成本效益研究方法及结果分析
M Campioni,I Agirrezabal,R Hajek et al.
M Campioni et al.
Objective: To predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients af...
Gerald J Pruckner,Thomas Schober,Katrin Zocher
Gerald J Pruckner
There is widespread agreement that behavior crucially influences one's health. However, little is known about what actually determines health-related behavior. We explore the impact of the place where many people spend most of their time, a...
Hendrik Jürges,Sophie-Charlotte Meyer
Hendrik Jürges
We use data on 11-15-year-old boys in the West Bank to study the empirical link between cognitive ability and health behavior, specifically (teen) smoking. Adjusting for both age in months and grade level allows us to effectively shut down ...
Correction to: Cost‑effectiveness analysis of stand‑alone or combined non‑invasive imaging tests for the diagnosis of stable coronary artery disease: results from the EVINCI study [0.03%]
对EVINCI研究结果的纠正：稳定型冠状动脉疾病诊断单独或联合无创检查的成本效益分析
Valentina Lorenzoni,Stefania Bellelli,Chiara Caselli et al.
Valentina Lorenzoni et al.
In the Published article, the value in the abstract has been published incorrectly. The correct abstract section is as follows.
James Gaughan,Panagiotis Kasteridis,Anne Mason et al.
James Gaughan et al.
A core performance target for the English National Health Service (NHS) concerns waiting times at Emergency Departments (EDs), with the aim of minimising long waits. We investigate the drivers of long waits. We analyse weekly data for all m...
The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France [0.03%]
真实世界证据在成本效益分析中的贡献——以法国达比加群酯为例
Gérard de Pouvourville,Patrick Blin,Pierre Karam
Gérard de Pouvourville
Objective: The goal of this study was to assess the differences between an ex ante and an ex post cost-effectiveness analysis of Dabigatran etexilate vs VKAs for the prevention of thromboembolic events in non-valvular atr...